Medtronic, Biosense tackle arrhythmias
This article was originally published in Clinica
Medtech giant Medtronic and Johnson & Johnson subsidiary Biosense Webster are to collaborate on exploring new technologies for better diagnosing and treating patients with cardiac arrhythmias. The companies said they intend to combine Biosense's know-how in cardiac imaging and navigation with Medtronic's expertise in cardiac monitoring and diagnostics to create a new care protocol for identifying patients most likely to have a successful ablation treatment. The firms will also integrate their respective technologies to develop new therapies for complex cardiac arrhythmias under a joint R&D programme.
You may also be interested in...
The Cincinnati, OH-based firm will pay $8m to recompense Unites States residents who purchased aerosol personal-care products potentially contaminated with benzene over a roughly six-year period.
An independent review of the US FDA’s food regulatory programs could renew a debate over splitting FDA into two agencies. That could be a distraction for the agency in the coming year – but it could also help keep the medical product review groups out of the political hot seat.
New proposed rule calls for replacing US FDA’s current annual reporting requirements for INDs with a safety update report that is consistent the format and content of the development safety update report (DSUR) supported by the International Council of Harmonisiation.